摘要
目的:探讨非小细胞肺癌(NSCLC)中肺腺癌差异表达基因(DAL-1)单核苷酸多态性(SNP)+1810T/C(rs8082898)与蛋白表达的关系及其对肿瘤发生发展的影响。方法:收集204例NSCLC石蜡组织及其配对正常淋巴结组织,以及112例NSCLC新鲜血液标本,采用PCR-RFLP检测DAL-1基因+1810T/C位点基因型;其中167例NSCLC及其配对癌旁组织SP法检测DAL-1蛋白表达;分析+1810T/C基因型与DAL-1蛋白表达及临床病理特征的关系。结果:在NSCLC中,TT组+1810T/C等位基因频率为92.72%(293/316),CT组为6.33%(20/316),CC组为0.95%(3/316),多态CT+CC组为7.28%(23/316);DAL-1蛋白表达阳性率TT组(59.74%,92/154)与CT+CC组(38.46%,5/13)差异无统计学意义,χ2=0.000,P>0.05。+1810T/C多态在Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期,χ2=11.003,P<0.05;淋巴结转移组高于无转移组,χ2=4.548,P<0.05。NSCLC组DAL-1蛋白表达阳性率(58.08%,97/167)低于对照组(90.42%,151/167),χ2=45.665,P<0.05;高中分化组(63.44%,59/93)高于低分化组(47.30%,35/74),χ2=4.365,P<0.05;Ⅰ期(72.31%,47/65)、Ⅱ期(54.29%,19/35)高于Ⅲ、Ⅳ期合组(46.27%,31/67),χ2=9.450,P<0.05;淋巴结转移组(37.08%,33/89)低于无转移组(82.05%,64/78),χ2=34.532,P<0.05。结论:DAL-1基因+1810T/C位点多态和蛋白表达降低可能在NSCLC的生长及淋巴结转移中发挥作用。
OBJECTIVE： To detect the single nucleotide polymorphism （SNP） ＋1810T/C （rs8082898） and expres- sion of DAL-1 in non-small cell lung cancer （NSCLC） and investigate their clinical significance. METHODS： Totally 204 paraffin-embeded tissue with matched normal lymph nodes and 112 blood specimens of NSCLC were detected for SNP ＋ 1810T/C by PCR-RFLP; 167 NSCLC with matched paracancerous tissue were examined the expression of DAL-1 by im- munohistochemical stain （SP）. RESULTS： The distribution of TT, CT, CC genotypes of the ＋ 1810T/C SNP in NSCLC were 92.72%（293/316） ,6.33%（20/316） and 0.95% （3/316）respectively and the polypeptide CT＋CC group was 7. 28%（23/316）. There was no significant difference between IT （59.74% ,92/154） and CT＋CC （38.46% ,5/13） in DAL-1 protein expression （Xz =0. 000, P〉0. 05）. Significantly increasing frequency of the patients carrying CT＋ CC genotype was observed in pT3 and pT4 compared to pT1 and pTz （Xz = 11. 003 ,P〈0. 05） ,also in tumors with lymph node metastasis compared to those without me- tastasis （X2 = 4. 548, P%0.05）. The positive expression rate of DAL-1 was 58.08 % （97/167） in NSCLC, lower than those of the control（90.42%, 151/167;xz ：45. 665 ,P〈0. 05）. Aberrant DAL-1 staining was more frequently observed in tumors with lymph node metastasis （37. 08% ,33/89） ,for stage I]I and 1V （46.27%,31/67） ,and for poorly differentiation （47. 30% ,35/74） ,com- pared with that of tumor without lymph node metastasis （82. 05% ,64/78） ,stage I （72. 31% ,33/89） and 1I （54. 29%, 19/35）, and high level differentiation （63.44 %, 59/93）,P%0.05. CONCLUSION： The ＋ 1810T/C SNP and aberrant exnression ofI）AL-1 may be involved in the progression and invasion of NSCLC.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2013年第5期321-325,共5页
Chinese Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(30971146)
广东省自然科学基金(S201210010181)
广东省科技计划(2009B030801350)
广东省自然科学基金博士启动(8451018201000858)
广东高校优秀青年创新人才培育项目(LYM08084)
广东省科技厅国际合作项目(2010B050700023)
广州市科技计划(2009Z1-E311)
广州市属高校科研项目(10A151)
